<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171635</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS0315(M00Y01)</org_study_id>
    <secondary_id>R01DK116126-01A1</secondary_id>
    <nct_id>NCT04171635</nct_id>
  </id_info>
  <brief_title>Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy</brief_title>
  <official_title>Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy in Transfusional Iron Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this research is to help develop a new magnetic resonance (MR) method,
      Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron
      concentrations without the need for a liver biopsy. Measurement of liver iron is important to
      diagnose and treat patients who have too much iron in their bodies (iron overload). Liver
      iron measurements by current MRI methods (R2 and R2*) can be inaccurate because of the
      effects of fat, fibrosis and other abnormalities. QSM should not be affected by these factors
      and should be free of these errors. In this study, MRI measurements (QSM, R2 and R2*) of iron
      in patients before liver transplant will be compared with chemical analysis of iron in liver
      explants (livers removed from patients undergoing liver transplant). The liver explants would
      otherwise be discarded. Investigators expect that this study will show that the new MRI
      method, QSM, is superior to the current MRI methods, R2 and R2*.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of this research is to improve the safety of iron-chelating therapy
      (ICT) in patients with transfusional iron overload by developing an accurate non-invasive
      measurement of the liver iron concentration (LIC), the best measure of the body iron burden
      in all forms of systemic iron overload. The scientific premise is that quantitative
      susceptibility mapping (QSM) provides a quantitative biophysical connection to LIC. Safe ICT
      requires careful adjustment of the iron chelator dose to the body iron burden to optimize
      iron excretion while avoiding chelator toxicity, including gastrointestinal disorders,
      audiovisual impairment, neutropenia, arthropathy, growth retardation, and hepatic and renal
      failure. QSM enables accurate measurement of LIC by overcoming the inherent cellular
      interference in current R2 (=1/T2) and R2* (=R2+R2') estimates that lack a well-defined
      biophysical connection to the LIC. A fundamental biophysical limitation of the R2 and R2*
      approaches is that intravoxel contents other than iron, including fibrosis, steatosis and
      necroinflammation, also alter relaxation. In the liver, paramagnetic iron stored in ferritin
      and hemosiderin is the dominant susceptibility source for QSM. Consequently, magnetic
      susceptibility measured by QSM has a simple linear relationship with the concentration of
      iron in the liver and is little affected by fibrosis, steatosis and necroinflammation. The
      investigator's research plan has 3 specific aims:

      Aim 1. Develop hQSM for accurate measurement of LIC without interfering errors. Investigators
      will optimize data acquisition and processing for free-breathing navigator acquisition with
      robust fat-water separation.

      Aim 2. Validate hQSM using histology and chemical measurement of LIC in liver explants.
      Investigators will assess the accuracies of LICs measured by hQSM and R2* in patients before
      liver transplant with histologic examination using the reference standard of chemical
      measurement of LIC in liver explants.

      Aim 3. Evaluate hQSM in patients with transfusional iron overload under ICT. In patients
      regularly transfused for thalassemia major, investigators will conduct a double-blind
      clinical study comparing the accuracy of hQSM and R2* in measuring annual changes in LIC,
      using regression against the year-long amount of iron administered in red blood cell
      transfusions and the year-long cumulative dose of iron chelator.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of efficacy of quantitative susceptibility mapping (QSM) MRI in quantifying liver iron concentration (LIC)</measure>
    <time_frame>Five years</time_frame>
    <description>Investigators will assess the accuracy of liver iron concentrations measured by QSM in patients before liver transplant with histologic examination using the gold standard chemical measurement of LIC in liver explants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrosis as determined by in vivo R2*, an MRI method that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>R2* is an imaging method used in MRI. R2* = (1/T2*) where R2* is a relaxation rate measured in units of Hz ([1/sec]). R2* is commonly used to look at iron levels by measuring the relaxation times of hydrogen nuclei affected by iron. The presence of the iron results in the shortening of proton relaxation times (T2*), thus increasing R2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis as determined by in vitro R2*, an MRI method that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>R2* is an imaging method used in MRI. R2* = (1/T2*) where R2* is a relaxation rate measured in units of Hz ([1/sec]). R2* is commonly used to look at iron levels by measuring the relaxation times of hydrogen nuclei affected by iron. The presence of the iron results in the shortening of proton relaxation times (T2*), thus increasing R2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis as determined by in vivo hQSM, an MRI post-processing technique that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>Quantitative susceptibility mapping (QSM) is widely used by the imaging research community in applications to detect iron. Tissue can become magnetized in response to a magnetic field, and the extent of magnetization is known as susceptibility, which arises from unpaired electrons in iron or external sources such as contrast agents. QSM permits visualization of the sizes and shapes of iron sources, delivers precise estimates of iron concentrations (units: parts per billion [ppb] or parts per million [ppm]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis as determined by in vitro hQSM, an MRI post processing technique that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>Quantitative susceptibility mapping (QSM) is widely used by the imaging research community in applications to detect iron. Tissue can become magnetized in response to a magnetic field, and the extent of magnetization is known as susceptibility, which arises from unpaired electrons in iron or external sources such as contrast agents. QSM permits visualization of the sizes and shapes of iron sources, delivers precise estimates of iron concentrations (units: parts per billion [ppb] or parts per million [ppm]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis as determined by in vivo R2*, an MRI method that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>R2* is an imaging method used in MRI. R2* = (1/T2*) where R2* is a relaxation rate measured in units of Hz ([1/sec]). R2* is commonly used to look at iron levels by measuring the relaxation times of hydrogen nuclei affected by iron. The presence of the iron results in the shortening of proton relaxation times (T2*), thus increasing R2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis as determined by in vitro R2*, an MRI method that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>R2* is an imaging method used in MRI. R2* = (1/T2*) where R2* is a relaxation rate measured in units of Hz ([1/sec]). R2* is commonly used to look at iron levels by measuring the relaxation times of hydrogen nuclei affected by iron. The presence of the iron results in the shortening of proton relaxation times (T2*), thus increasing R2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis as determined by in vivo hQSM, an MRI post-processing technique that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>Quantitative susceptibility mapping (QSM) is widely used by the imaging research community in applications to detect iron. Tissue can become magnetized in response to a magnetic field, and the extent of magnetization is known as susceptibility, which arises from unpaired electrons in iron or external sources such as contrast agents. QSM permits visualization of the sizes and shapes of iron sources, delivers precise estimates of iron concentrations (units: parts per billion [ppb] or parts per million [ppm]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis as determined by in vitro hQSM, an MRI post-processing technique that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>Quantitative susceptibility mapping (QSM) is widely used by the imaging research community in applications to detect iron. Tissue can become magnetized in response to a magnetic field, and the extent of magnetization is known as susceptibility, which arises from unpaired electrons in iron or external sources such as contrast agents. QSM permits visualization of the sizes and shapes of iron sources, delivers precise estimates of iron concentrations (units: parts per billion [ppb] or parts per million [ppm]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necroinflammation as determined by in vivo R2*, an MRI method that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>R2* is an imaging method used in MRI. R2* = (1/T2*) where R2* is a relaxation rate measured in units of Hz ([1/sec]). R2* is commonly used to look at iron levels by measuring the relaxation times of hydrogen nuclei affected by iron. The presence of the iron results in the shortening of proton relaxation times (T2*), thus increasing R2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necroinflammation as determined by in vitro R2*, an MRI method that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>R2* is an imaging method used in MRI. R2* = (1/T2*) where R2* is a relaxation rate measured in units of Hz ([1/sec]). R2* is commonly used to look at iron levels by measuring the relaxation times of hydrogen nuclei affected by iron. The presence of the iron results in the shortening of proton relaxation times (T2*), thus increasing R2*.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necroinflammation as determined by in vivo hQSM, an MRI post-processing technique that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>Quantitative susceptibility mapping (QSM) is widely used by the imaging research community in applications to detect iron. Tissue can become magnetized in response to a magnetic field, and the extent of magnetization is known as susceptibility, which arises from unpaired electrons in iron or external sources such as contrast agents. QSM permits visualization of the sizes and shapes of iron sources, delivers precise estimates of iron concentrations (units: parts per billion [ppb] or parts per million [ppm]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Necroinflammation as determined by in vitro hQSM, an MRI post-processing technique that provides quantitative information on iron levels</measure>
    <time_frame>Five years</time_frame>
    <description>Quantitative susceptibility mapping (QSM) is widely used by the imaging research community in applications to detect iron. Tissue can become magnetized in response to a magnetic field, and the extent of magnetization is known as susceptibility, which arises from unpaired electrons in iron or external sources such as contrast agents. QSM permits visualization of the sizes and shapes of iron sources, delivers precise estimates of iron concentrations (units: parts per billion [ppb] or parts per million [ppm]).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">42</enrollment>
  <condition>MRI Scans</condition>
  <arm_group>
    <arm_group_label>Patients with transfusional iron overload</arm_group_label>
    <description>The subject population of patients with transfusional iron overload awaiting liver transplant has been chosen because of the clinical indication for MRI examination every three months and the availability of liver explants for analysis after transplant. Explants will receive QSM or R2* MRI to provide a quantitative biophysical connection to liver iron concentration (LIC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Healthy control subjects over the age of 21 with no known hematological or liver disease and no contraindications for MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with transfusional iron overload</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>R2* Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patients with transfusional iron overload</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver explants to be obtained from the Department of Pathology and Cell Biology at Columbia
      after all clinical pathological examinations have been completed and the specimens would
      otherwise be discarded. Specimens are initially stored with identifying information but will
      be de-identified by the Study Pathologist prior to transport to Weill Cornell Medicine.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects will be selected from the community through personal contact and written
        description of the research, and online advertising.

        Subjects will be selected at Columbia from those awaiting liver transplant to be enrolled
        in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of thalassemia major

          -  Treatment with deferasirox formulated as JadenuÂ® as the sole iron chelating therapy
             (ICT)

          -  Regular transfusion with records maintained in the Cornell Thalassemia Program

          -  2 years of age or older

          -  Females who are not pregnant

        Inclusion Criteria (for healthy subjects):

          -  Men and women aged 21 years or older

          -  Able and willing to give consent

          -  No known hematological and liver disease

          -  No contraindications for MRI

        Exclusion Criteria:

          -  A history of auditory or ocular toxicity related to ICT

          -  A history of poor adherence to prescribed therapy

          -  An inability to tolerate MRI examinations

          -  Treatment for mental illness

          -  Institutionalization or imprisonment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary M Brittenham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sujit S Sheth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary M Brittenham, MD</last_name>
    <phone>212-305-7005</phone>
    <email>gmb31@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Gary M Brittenham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Koehne de Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quantitative Susceptibility Mapping</keyword>
  <keyword>Iron chelating therapy</keyword>
  <keyword>Iron overload</keyword>
  <keyword>Liver iron concentration</keyword>
  <keyword>erythrocyte transfusion</keyword>
  <keyword>liver transplantation</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>thalassemia major</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

